Fan et al. (2014) revealed that MALAT1 level was higher in primary tumors that subsequently metastasized than those in non-metastatic bladder cancer, and suggested that MALAT1 inhibition may represent a promising therapeutic option for suppressing bladder cancer progression. This evidence concerns the gene MALAT1 and urinary bladder cancer.